Sequent Scientific , a prominent player in the life sciences sector, has initiated a postal ballot process to seek shareholder approval for the appointment of Mr. Anuj Poddar as a Non-Executive Director. This move comes as part of the company's efforts to strengthen its board with experienced professionals.

Key Details of the Appointment

• Mr. Anuj Poddar was initially appointed as an Additional Non-Executive Director on September 5, 2025.
• The company is now seeking shareholder approval to formalize his position as a Non-Executive Director.
• If approved, Mr. Poddar will serve as a nominee of The Carlyle Group on Sequent Scientific's board.

Voting Process

• The remote e-voting period will run from October 4 to November 2, 2025.
• Results of the postal ballot are expected to be announced by November 4, 2025.
• The cut-off date for voting eligibility is set at September 26, 2025.

About Anuj Poddar

Mr. Anuj Poddar brings a wealth of experience to Sequent Scientific:

• Currently serves as Managing Director and Asia Co-Head of Global Portfolio Solutions at Carlyle, a global investment firm managing $465.00 billion in assets.
• Previously held the position of Managing Director and CEO at Bajaj Electricals, where he drove significant transformation and value creation.
• Has over 13 years of experience with Viacom18 Media, playing a key role in the company's growth.
• Holds a rank in Chartered Accountancy and is an Aspen Fellow.

Board's Rationale

The Nomination and Remuneration Committee and the Board of Directors believe that Mr. Poddar's induction will bring valuable experience to Sequent Scientific, particularly in light of increasing business complexities and evolving regulatory landscapes.

Remuneration

It's noteworthy that Mr. Poddar will not receive any sitting fees or commission for his role. However, he will be entitled to reimbursement of expenses incurred on behalf of the company, in line with company policy.

Sequent Scientific's move to appoint Mr. Anuj Poddar reflects the company's commitment to enhancing its board's expertise and strategic capabilities. Shareholders will have the opportunity to vote on this appointment, potentially shaping the future direction of the company's governance and strategic initiatives.

Sequent Scientific , a listed animal health company, has received overwhelming support from its public shareholders for its proposed merger with Viyash Life Sciences, a privately-held human health firm. The merger, valued at ₹8,000.00 crore, marks a significant move in the healthcare sector, combining expertise in animal and human health under one roof.

Key Highlights of the Merger

• Shareholder Approval: 99.98% of Sequent Scientific's public shareholders voted in favor of the merger on August 30.
• Merger Value: The deal is estimated at ₹8,000.00 crore.
• Portfolio Combination: The merger brings together Carlyle's portfolio companies from animal health (Sequent) and human health (Viyash) sectors.

Leadership and Ownership Structure

• New Leadership: Hari Babu Bodepudi, founder of Viyash Life Sciences and former global COO of Mylan, is set to become the group CEO-designate of the merged entity.
• Ownership: Post-merger, Bodepudi will become the second-largest shareholder, holding just under 10% stake. Carlyle will remain the largest shareholder.

Operational Synergies

• Manufacturing Capacity: The combined entity will operate 15-16 manufacturing sites.
• Contribution: Viyash Life Sciences will bring 9 manufacturing sites to the merger, enhancing backward integration capabilities for Sequent.
• Strategic Benefits:
  • Sequent gains access to generics opportunities in animal health products.
  • Viyash can leverage Sequent's relationships with innovator companies in the companion animal segment.

Industry Impact

The merger represents a strategic move to create a more vertically integrated and diversified healthcare company. By combining Sequent's strengths in animal health with Viyash's human health expertise, the new entity is positioned to explore synergies across both sectors.

This consolidation reflects the growing trend of integration between various healthcare segments, potentially leading to more efficient drug development and manufacturing processes that could benefit both animal and human health markets.

The strong shareholder approval indicates confidence in the merger's potential to create value and drive growth in the competitive healthcare landscape.